Physician profile
Mark E Tafoya
NPI 1639233448
$5,386.94
in general payments reported to CMS, 2019-2025
17 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,779 · 2020: $290 · 2021: $316 · 2022: $299 · 2023: $1,054 · 2024: $843 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,563 · Entertainment: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,563.40 |
| Entertainment | $138.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,195.09 | 2019-2024 | Vabysmo, Susvimo |
| Alcon Vision LLC | $707.22 | 2019-2025 | Unity |
| Regeneron Healthcare Solutions, INC. | $631.26 | 2019-2024 | Eylea Hd |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $433.80 | 2019-2021 | |
| Optos, INC. | $326.86 | 2021-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Horizon Therapeutics Plc | $300.20 | 2023 | Tepezza |
| Amgen INC. | $280.45 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $266.27 | 2019 | |
| Apellis Pharmaceuticals, INC. | $241.08 | 2024-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $204.45 | 2019 | |
| Eyepoint US, INC. | $173.12 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $133.86 | 2025 | Xdemvy |
| Dompe US, INC. | $128.49 | 2025 | Oxervate |
| Allergan, INC. | $115.59 | 2019 | |
| Mallinckrodt Hospital Products INC. | $114.97 | 2025 | Acthar |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $103.18 | 2021 | |
| Harrow Eye, LLC | $31.05 | 2025 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tafoya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.